BlueReg has extensive experience in writing safety documents in a wide variety of settings and different stages of the product lifecycle.
The experienced team can support with assessing a product risk benefit profile and writing a Risk Management Plan (RMP), Development Safety Update Report (DSUR), Periodic Benefit-Risk Evaluation Report (PBRER) and early access reports. Furthermore, BlueReg can provide support to update the Summary of Product Characteristics (SmPC) for safety reasons.
All these activities are carried out in full compliance with Good Vigilance Practices and local standards.
Associated News
Consulting Regulatory Affairs Services for Pharmaceutical companies
The regulatory affairs process is a critical component of the safe development, registration and...
Download now
The regulatory affairs process is a critical component of the safe development, registration and...
Corinne Schmitz, CEO of BlueReg, winner of the Women Equity 2020 Award
Doctor of Pharmacy, Corinne Schmitz has worked for more than twenty years in the pharmaceutical...
The French system for preventing and managing shortages
The French regulation on the prevention and management of stock shortages of medicinal products is...